semaglutide hashimoto's Hashimoto's Disease and Ozempic: Safety

Seino, Y., Rasmussen, M

It reduces glucagon production, the hormone prompting the liver for glucose productionhence preventing excess glucose

Biol Chem 384:575588

Phase II clinical trial results demonstrated: Body weight reduction of up to 2% at 48 weeks (vs 2.1% placebo) 83% of participants achieved 15% body weight loss at 12 mg weekly dose HbA1c reduction of up to 02% in participants with Type 2 Diabetes Normalization of liver fat in 86% of participants with hepatic steatosis Reduction in systolic blood pressure averaging 6-8 mmHg These findings are preliminary

This is designed not for results, but for acclimation